Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0025202 (
melanoma
)
69,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The 45-year history of research in
cancer
therapy involving ultrasound may be divided into the four periods of initiation, enthusiasm, pessimism and revival. There have been three approaches to the subject: studies have sought to measure the effects on tumors of a) ultrasound alone; b) ultrasound in combination with radiotherapy, and c) ultrasound in combination with chemotherapy. With the first approach the results have varied. In some cases, decreased growth rates or regressions of tumors have been reported; in other cases, either no effect has been observed or growth has been increased. With the second approach, for some tumors, combined treatment has produced greater effects on tumors than has x-ray alone, whereas in other tumors the addition of ultrasound has produced no change. With the third approach, enhancement of the effects of drugs has been observed in
melanoma
and mouse tumor cells treated with ultrasound and several anticancer drugs. The mechanism of action in most (but not all) cases has appeared to be absorption heating. The potential of ultrasound to provide local tumor control and to enhance other therapy modes has motivated the current efforts by several groups to further study and understand it actions on
malignancies
.
...
PMID:Cancer therapy with ultrasound: a historical review. 11 18
Serum tyrosinase activity in many persons with metastatic diseases was found to be significantly higher than activity in normal persons. The highest activity was observed in
melanoma
and breast carcinoma. The electrophoretic patterns of serum tyrosinase, resolved by electrophoresis of a serum tyrosinase fraction followed by incubation of the gel sample with L-dopa, and represented as sets of RF's of melanin bands, were characteristically different in
melanoma
, breast carcinoma, and certain other diseases. The RF's of melanin and protein bands in the serum enzyme preparations from
melanoma
patients were concisely defined. Further, some potent serum fractions inhibiting tyrosinase melanogenic activity have been obtained, and the presence of tyrosinase inhibitors in the serum enzyme preparation has also been demonstrated. More detailed exploration of these serum tyrosinase parameters may provide more specific and sensitive detection for certain malignant diseases.
Cancer
Res 1979 Sep
PMID:Serum tyrosinase in malignant disease, its activity, and the electrophoretic patterns of the enzyme as carried by immunoglobulins'. 11 92
The relationships between differentiation and malignant transformation were studied in human malignant melanomas in vivo and in vitro. Melanocyte differentiation was assessed by ultrastructural morphological characteristis (the appearance of the melanosomes and related structures) localization of dopa-oxidase and assay of 5-S-cysteinyldopa, a specific metabolite. The transformed characteristic of the cells in vitro was evaluated by their ability to give rise to established cell lines, karyological modifications and heterotransplantation in Nude mice and Syrian hamsters. Morphological variability of the cells in malignant melanomas is accompanied by variability in the localization of dopa-oxidase, the level of 5-S-cysteinyldopa, chromosome pattern and their heterotransplantibility. The lack of pigmentation in some
malignant melanoma
lines can result from either an irreversible loss of some functions which give rise in melanization and the
malignancy
in maintained, or by phenomenon of regulation determined by intra or extra-cellular factors with the loss of heterotransplantability. Modulation phenomena affecting tumorigenicity and pigmentation although sometimes concomitant are not identical.
Bull
Cancer
1979
PMID:[Correlation between differentiation and malignancy in human malignant melanocytes "in vivo" and "in vitro" (author's transl)]. 11 47
Bovine pineal polypeptide extract (PPE) exerted an anti-tumor effect on mouse-transplantable tumors: mammary
cancer
(RSM), squamous cell cervical carcinoma (SCC), hepatoma-22a and lympholeukemia LIO-1, and had no effect on Harding-Passey
melanoma
and leukemia L-1210. It was shown that PPE possessed the ability to decrease the incidence of DMBA-induced mammary adenocarcinomas in rats. The daily administration of 0.5 mg PPE prolonged the life span of rats by 25% and failed to influence spontaneous tumor development. The arguments in favor of a possible mechanism of anti-tumor action of the pineal gland are submitted. It is suggested that the anti-tumor effect of PPE may occur when the syndrome of cancrophilia is induced by tumor transplantation or chemical carcinogens.
...
PMID:Study of the anti-tumor effect of polypeptide pineal extract. 11 14
The tyrosinase activity in two sucrose gradient isolated melanosome fractions from a melanotic hamster
melanoma
was found to increase after alpha-chymotrypsin treatment. The enhancement in tyrosinase activity had its maximum at a concentration of 1 mg/ml alpha-chymotrypsin after 120 min incubation at 37 degrees C. No direct activating effect of alpha-chymotrypsin was found either on the soluble tyrosinase fraction from freshly prepared untreaed whole-tumor homogenate or on purified mushroom tyrosinase. The activating effect of alpha-chymotrypsin upon the melanosome tyrosinase is believed to be due to the endopeptidic hydrolysis of the--CO--NH--bound existing between tyrosinase and tyrosine and phenylalanine residues in the melanin molecule. Although alternative interpretations are not excluded, the observed enhancement in tyrosinase activity after alpha-chymotrypsin treatment of melanosomes might indicate the existence of an "enzyme liberating" mechanism in the melanosomes.
J
Cancer
Res Clin Oncol 1979 Oct
PMID:Chymotrypsin activation of melanosome tyrosinase in hamster melanotic melanoma. 11 73
The antitumor activity of 1-alkyl carbamoyl derivatives of 5-fluorouracil against Lewis lung carcinoma and B16
melanoma
by long-term oral administration was examined. The 1-hexyl and 1-phenethyl carbamoyl-5-fluorouracil derviatives were markedly active against early Lewis lung carcinoma among the derivatives tested. These compounds were not markedly active against advanced Lewis lung carcinoma but did show acceptable activity. Increases in lifespan in mice with early Lewis lung carcinoma at optimal doses of 1-hexyl and 1-phenethyl carbamoxyl-5-fluorouracil were 98% and 78% respectively. In advanced Lewis lung carcinoma, the 1-hexyl derivative was active by either intermittent or daily administration, but the 1-phenethyl derivative was active only by daily administration. Lung metastases were not inhibited by optimal doses of the 1-hexyl derivative but were completely inhibited by the 1-phenethyl derivative. The 1-hexyl derivative was also active against B16
melanoma
and the increase in lifespan at optimal doses was 27%. As a result, 1-hexyl carbamoyl-5-fluorouracil was found to be the most active derivative against early Lewis lung carcinoma and B16
melanoma
. However, 1-phenethyl carbamoyl-5-fluorouracil was the most active derivative against advanced Lewis lung carcinoma by daily administration and this compound completely inhibited lung metastases, while 5-fluorouracil and cyclophosphamide did not inhibit lung metastases.
Cancer
Treat Rep
PMID:Antineoplastic effect of orally administered 1-alkyl carbamoyl derivatives of 5-fluorouracil on sc implanted Lewis lung carcinoma and B16 melanoma. 11 2
The mitogens concanavalin A (Con A) and bacterial lipopolysaccharide (LPS) stimulated normal spleen cells of DBA/2J, CBA/J, and BALB/c mice about equally in the presence of either isologous or homologous serum. This system revealed that sera from mice with five different methylcholanthrene-induced rhabdomyosarcomas inhibited mitogen stimulation of normal spleen cells. Sera from mice with a mammaryadenocarcinoma and spontaneous rhabdomyosarcoma were similarly suppressive. In contrast, sera from mice with
melanoma
were not inhibitory and often enhanced stimulation. Sera from tumor-bearing animals had the same effects both qualitatively and quantitatively on cells from the strain carrying the tumor and on cells from the other two strains. The mixed lymphocyte response of CBA/J times BALB/c spleen cells was affected exactly as were the responses to mitogen by the various sera. Stimulation by mitogen of mouse lymph-node cells and spleen cells with macrophages removed, as well as that of guinea pig spleen cells, was also inhibited by sera from mice with rhabdomyosarcoma and mammary adenocarcinoma.
J Natl
Cancer
Inst 1975 Mar
PMID:Effects of sera from tumor-bearing mice on mitogen and allogeneic cell stimulation of normal lymphoid cells. 12 99
Viable frozen lymphocytes displayed activity in blastogenesis assays that was indistinguishable from freshly prepared lymphoid cells. Similarly, cytotoxic activity of lymphocytes against
melanoma
target cells from
melanoma
patients was only slightly affected by the freezing procedure. Frozen lymphocytes provided a highly reproducible source of cells in these assays. The use of viable frozen peripheral blood lymphoid cells for the retrospective analysis of a
cancer
patient's immune response is described.
...
PMID:The use of viable frozen lymphocytes for studies in human tumor immunology. 12 84
The immunologic effects of leukapheresis on
cancer
patients and three other groups of donors using the continuous-flow blood cell separator are presented according to the protocol described in the preceding article. Transient declines were noted in per cent T-lymphocytes of some, but not all, leukapheresed normal donors and
cancer
patients. These declines were comparable to the small declines observed in sham donors and the fluctuations in per cent T-lymphocytes noted in individuals who did not undergo leukapheresis. There were no changes in lymphocyte-mediated cytotoxicity to a
melanoma
cell line in 2 of 4
melanoma
patients, while values in 2 patients fell by about one-half within 4 hours and returned to preleukapheresis levels by 24 hours. Release of macrophage migration inhibition factor by lymphocytes from all 4
cancer
patients and 4 normal donors, in whom this parameter was studied, fell transiently and returned to preleukaphresis levels within 24 hours. Blastogenic responses of lymphocytes from
cancer
patients and normal donors to phytohemagglutinin (PHA) and in one way mixed lymphocyte reactions increased in several individuals and decreased slightly in others. There appears to be no significant immunosuppressive effects (within the parameters studied) of a single leukapheresis for lymphocytes on the blood cell separator, since changes in lymphocyte parameters were relatively minor, transient, and variable and, where studied, paralleled fluctuations observed in sham donors and individuals not undergoing leukapheresis.
...
PMID:Effects on cancer patients of leukapheresis with the continuous-flow blood cell separator. II. Immunologic parameters in vitro. 12 18
Testing of delayed hypersensitivity responses to recall antigens, newly encountered antigens and tumor antigens has contributed to the understanding of several immunologic factors in human neoplasia. Patients with Hodgkin's disease tend to have depressed responses to both newly encountered and recall antigens. Patients with solid tumors are more likely to be deficient only in the response to newly encountered antigens. In patients who have intact response to recall antigens, reactivity to antigen preparations from tumor and control tissue may be studied. Tumor-associated or organ-associated antigens have been demonstrated by delayed hypersensitivity responses in leukemia, Burkitt's lymphoma,
malignant melanoma
and carcinoma of the lung, breast, cervix uteri and intestine. Approaches to a definition of the specificity of these reactions are described. The results with these tumor antigen tests correlate strongly with the clinical course. This is a promising technique for monitoring immunotherapy. The results from tests with recall and newly encountered antigens also correlate with the clinical status and perhaps with prognosis. Various possible interpretations of these changes are discussed. Further work should be directed toward an exact definition of immunologic defects in patients with
cancer
and toward the use of this understanding for a rational program of immunotherapy.
...
PMID:Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions. 12 44
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>